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Pulmonary arterial hypertension (PAH) is a 
disease of the small pulmonary arteries that is 
characterized by vascular proliferation and re-
modeling, with progressive increases in pulmo-
nary vascular resistance leading to right heart 
failure and, ultimately, death (1, 2). Although 
PAH may be idiopathic, familial, or secondary 
to multiple distinct diseases, there are common 
pathophysiological features, including remod-
eling of the pulmonary vessel wall, vasocon-
striction, and thrombosis (3). The cellular and 
molecular events underlying the evolution of 
these changes are under investigation and con-
tinue to guide the development of potential 
therapeutics (4, 5). A substantial number of 
molecules and molecular pathways have been 
implicated. Impaired production of vasoactive 
nitric oxide (NO) or prostacyclins, or overex-
pression of vasoconstrictors such as  endothelin-1 
can alter pulmonary vascular tone and lead to 
vascular remodeling (6–9). Alterations in these 
vasoactive molecules suggest that endothelial 
dysfunction plays a key role.
Previous experiments have illustrated that in-
duced expression of heme oxygenase–1 (HO-1; 
the gene is referred to as hmox-1), the induc-
ible heme-degrading enzyme, given before the 
disease-causing stimulus is protective against 
the development of PAH. Induction of HO-1 
protects against vascular remodeling and the 
development of PAH in chronic hypoxia in 
rats, and hmox-1−/− mice exhibit an exagger-
ated response to chronic hypoxia compared 
with wild-type mice (10, 11). The mechanism 
by which HO-1 induction can prevent PAH 
has been elusive. Insight, however, was gar-
nered by Minamino et al., who showed that 
transgenic mice that overexpress HO-1 in a 
small population of epithelial cells of the lung 
were protected against pulmonary infl  amma-
tion, PAH, and vessel wall hypertrophy in re-
sponse to hypoxia (12). These data strongly 
suggest that a soluble mediator generated by 
HO-1 mediated the protection aff  orded  in 
the pulmonary vasculature. The gaseous mol-
ecule carbon monoxide (CO), which arises 
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Pulmonary arterial hypertension (PAH) is an incurable disease characterized by a progres-
sive increase in pulmonary vascular resistance leading to right heart failure. Carbon monox-
ide (CO) has emerged as a potently protective, homeostatic molecule that prevents the 
development of vascular disorders when administered prophylactically. The data presented 
in this paper demonstrate that CO can also act as a therapeutic (i.e., where exposure to CO 
is initiated after pathology is established). In three rodent models of PAH, a 1 hour/day 
exposure to CO reverses established PAH and right ventricular hypertrophy, restoring right 
ventricular and pulmonary arterial pressures, as well as the pulmonary vascular architec-
ture, to near normal. The ability of CO to reverse PAH requires functional endothelial nitric 
oxide synthase (eNOS/NOS3) and NO generation, as indicated by the inability of CO to 
reverse chronic hypoxia-induced PAH in eNOS-defi  cient (nos3−/−) mice versus wild-type 
mice. The restorative function of CO was associated with a simultaneous increase in apop-
tosis and decrease in cellular proliferation of vascular smooth muscle cells, which was 
regulated in part by the endothelial cells in the hypertrophied vessels. In conclusion, these 
data demonstrate that CO reverses established PAH dependent on NO generation support-
ing the use of CO clinically to treat pulmonary hypertension. 
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endogenously from all cells via the catabolism of heme by 
the heme oxygenase enzymes, possesses salutary actions in 
numerous disease models when administered exogenously 
at low, nontoxic concentrations (13). We and others have 
previously demonstrated that CO substantially diminishes 
vascular intimal hyperplasia after direct mechanical and trans-
plant-related immunological injuries, as well as hypoxia-
  induced PAH (14–17). In these injury models, inhaled CO 
was administered before the development of vascular injury. 
The eff  ects of CO in these models have been attributed to 
both cyclic guanosine 3′,5′-monophosphate–dependent and 
–  independent modes of action. Moreover, studies have dem-
onstrated that CO derived from heme oxygenase expression 
may mediate decreased pulmonary artery vascular resistance 
Figure 1.  CO protects against and reverses MCT-induced experi-
mental PAH in rats. (A) Kinetics demonstrating increasing mPAP at 2, 4, 
and 6 wk after a single s.c. injection of MCT on day 0. Results represent 
means ± SD of six to eight rats/group. *, P < 0.02 versus untreated rats. 
(B) Representative histological specimen of pulmonary arteriole 6 wk after 
MCT treatment with and without exposure to 250 ppm CO on days 29–42. 
Note that MCT increases medial expansion without thrombosis, whereas 
those animals treated with CO showed considerably reduced vascular 
hyperplasia. Images are representative of six to eight sections/lung from 
four to six rats. (C) CO reverses MCT-induced pulmonary arteriolar thick-
ening in rats treated with CO on days 29–42 after MCT. Data are presented 
as percent wall thickness calculated as the area bounded by the internal 
and external laminae (see Materials and methods). Results represent 
means ± SD of 10 vessels from the lungs of fi  ve rats/group. *, P < 0.02 
versus CO and CO/MCT. (D) In the genetically predisposed FHH rats, a sig-
nifi  cant reduction in mean RV pressures (which is refl  ective of mPAP) was 
observed in those animals treated with CO. Results represent means ± SD 
of four to six rats/group. *, P < 0.01 versus air- and CO-treated rats.
Table I.  Effect of CO on MCT-induced changes in body weights, cardiac weights, and pulmonary hemodynamics in rats
No MCT MCT
Air CO Air
CO 
(days 1–14)
CO 
(days 15–28)
CO 
(days 29–42)
Number (n) 66866 9
BW (g) 288 ± 31 291 ± 37 249 ± 52 303 ± 56 296 ± 53 301 ± 70
mPAP (mmHg) 15.8 ± 0.75 16.1 ± 1.0 34.6 ± 2.8# 15 ± 2* 19.8 ± 2.7* 21.1 ± 4.0*
RV mass (mg) 143 ± 21 137 ± 19 414 ± 27# 165 ± 21* 207 ± 51* 214 ± 59*
LV + IVS (mg) 524 ± 29 530 ± 33 696 ± 15 617 ± 178 639 ± 196 690 ± 156
RV/BW 0.49 ± 0.01 0.47 ± 0.04 1.66 ± 0.15# 0.54 ± 0.06* 0.69 ± 0.1* 0.71 ± 0.2*
RV/LV + IVS 0.26 ± 0.01 0.26 ± 0.03 0.60 ± 0.05# 0.28 ± 0.05* 0.33 ± 0.06* 0.31 ± 0.07*
PAH was assessed on day 43 following MCT treatment. MCT induced signifi  cant PAH (air vs. no MCT) as assayed by mPAP, RV mass, and the ratios of RV/BW and RV/LV + IVS. 
CO treatment, when started on days 1–14, 15–28, or 29–42, prevented or reversed MCT-induced changes in the heart and lung parameters listed. n = number of animals/
group. #, P < 0.01 versus no MCT; and *, P < 0.01 versus air + MCT. BW, body weight.JEM VOL. 203, September 4, 2006  2111 
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and inhibit hypoxic vasoconstriction (18–20). CO also exerts 
potent antiinfl  ammatory eff  ects, inhibits platelet aggregation, 
and can be pro- or antiapoptotic depending on the cell type 
(16, 21). There is no information whether CO might act 
therapeutically to treat and modulate established PAH.
We hypothesized that CO treatment would ameliorate 
and reverse PAH even when given after PAH pathology has 
been established (i.e., as a therapeutic that is therefore clini-
cally relevant). There is one published study demonstrating 
that inhaled CO can prevent the development of hyperten-
sion (17), but in that study CO was administered continu-
ously and initiated at the time of hypoxia, which clinically is 
not relevant. Our data in this paper would off  er a potential 
approach that could be tested in the clinical setting, where 
pretreatment is not an option. We therefore designed our 
treatment regimens based on this premise, using three well-
established models of PAH in rodents. Although these are 
well characterized and accepted models of hypertension, 
complete extrapolation to human disease remains limited.
RESULTS
CO reverses pulmonary hypertension in rats
Monocrotaline sodium (MCT), chronic hypoxia, and the 
genetically susceptible fawn-hooded hypertensive (FHH) 
rat strains were used to evaluate the eff  ects of CO on PAH. 
  Exposure to CO at 250 ppm for 1 h increases COHb to 
 19%, which correlates to the accepted Coburn computa-
tion for this exposure regimen (18). The COHb levels return 
to baseline (<1%) within 3–4 h after discontinuing CO. In 
the MCT model, the development of PAH was examined 
at 2, 4, and 6 wk after MCT treatment (Fig. 1 A). The de-
velopment of PAH was progressive, and by 2 wk MCT in-
duced signifi  cant (P < 0.02) PAH as determined by the mean 
pulmonary arterial pressure (mPAP), right ventricle (RV)/ 
left ventricle (LV) + intraventricular septum (IVS) mass ratio 
and the RV/body mass ratio. These data show that there is 
signifi  cant PAH established by 2 wk after MCT and allow 
us to determine if CO can act as a therapeutic to reverse 
established PAH.
We tested various times after the start of MCT treatment 
to begin CO administration. Our fi  rst experiments tested 
CO administration starting only 1 d after MCT. 250 ppm 
CO was delivered as an inhaled gas for 1 h/d on days 0–14 
(after MCT administration) of the experiment. PAH was as-
sessed at 6 wk. This early pretreatment regimen of CO pre-
vented the development of PAH (Table I). We next extended 
the time course to evaluate the eff  ects of CO when delivered 
only on days 15–28 or days 29–42 after starting MCT, time 
points at which there were already cardiopulmonary patho-
physiologic changes associated with PAH. CO treatment on 
days 15–28 or 29–42 signifi  cantly reversed mPAP and pre-
vented further progression of PAH based on the RV/LV + 
IVS and RV/body mass ratios (P < 0.01; Table I). Addition-
ally, histological analyses showed a considerable reduction in 
pulmonary arterial hyperplasia, as evident by increased medial 
expansion of the smooth muscle cells. (Fig. 1 B). Vascular 
morphometric measurements of the smaller pulmonary arte-
riolar changes induced in response to MCT showed the well-
described increase in medial wall thickness and lumen (wall 
ratios further characterizing the injury are shown in Fig. 1 C). 
Exposure to CO on days 29–42 showed a signifi  cant reduc-
tion of wall thickness from 2.1 ± 0.09 to 1.4 ± 0.1 (P < 
0.01), supporting the fi  ndings in mPAP and right ventricular 
hypertrophy (RVH). Determination of COHb levels in rats 
exposed to 1 h of CO at 250 ppm reached a concentration of 
19 ± 1.5% from baseline concentrations of 1.2 ± 0.5% (P < 
0.001) and returned to baseline within 4–6 h, which is ex-
pected based on standard Coburn calculations.
To corroborate and support the fi  ndings with MCT, we 
used two additional well-described models of PAH in rats: 
Figure 2.  CO protects against and reverses chronic hypoxia-
 induced experimental PAH in rats. (A–C) CO reverses pathology asso-
ciated with chronic hypoxia-induced PAH, including restoring body 
weights (A) and lowering hypoxia-induced increases in mPAP (B), as well 
as RV/LV + IVS ratios (C). Results represent means ± SD of six rats/
group. *, P < 0.01 versus CO/hypoxia- and air-treated controls.2112   CARBON MONOXIDE TO TREAT HYPERTENSION | Zuckerbraun et al.
the chronic hypoxia–exposed rat and the FHH rat, which 
is genetically predisposed to the development of PAH and 
its pathology by 12–16 wk of life in the absence of hypoxia. 
A similar exposure regimen was implemented in these two 
models. CO exposure of the FHH rats was begun at 12 wk 
of age, when there was a signifi  cant increase in right ventric-
ular pressure that resolved to near normal in response to CO 
(24 ± 1.7 mmHg in air vs. 12 ± 1 mmHg in CO-treated an-
imals; P < 0.01; Fig. 1 D). In the hypoxia model, rats were 
exposed to 10% O2 for 6 wk. 3 wk from the start of the expo-
sure, at which point PAH is well established, the CO expo-
sure regimen (250 ppm for 1 h/d) was implemented for the 
additional 3 wk. After each daily 1-h exposure to CO, the 
rats were returned to hypoxic conditions. Control animals 
were removed and exposed to room air for the 1-h period 
and then returned to hypoxia. Chronic exposure to hypoxia 
leads to a decrease in body weight with time. An initial in-
dication of the benefi  cial eff  ects of CO administration was 
observed here with an increase in body weights compared 
with untreated hypoxia/air controls (P < 0.01; Fig. 2 A). 
Figure 3.  CO ameliorates MCT-induced PAH via blocking prolif-
eration and increasing apoptosis of the vascular smooth muscle 
cells in the pulmonary artery. Lungs from rats treated with MCT in the 
presence and absence of 250 ppm CO for 1 h/d (initiated 3 wk after in-
duction of PAH) were harvested on day 43, fi  xed, sectioned, and stained 
for markers of proliferation and apoptosis. The majority of positive stain-
ing colocalized to smooth muscle cells. Vascular smooth muscle cell pro-
liferation, as determined by Ki67 immunostaining, was not present in 
untreated animals (A), but it was increased in hypoxia- and MCT-induced 
PAH (hypoxia is shown; B) and substantially decreased by CO treatment 
(C). Images are representative of six to eight sections/lung from four to 
six rats/group. Cellular apoptosis, as determined by TUNEL staining, is 
absent in untreated and hypoxia-treated rats (E and F, respectively); how-
ever, sections from chronic hypoxia-treated animals treated with CO for 
1 h/d resulted in a considerable increase in TUNEL-positive smooth muscle 
cells (G). The arrows in F and G represent positively stained cells. (I–K) 
Representative images from the same animals as above (E–G), immuno-
stained for activated caspase-3. Arrows designate positive peroxidase 
staining. Note that the relative number of caspase-3–positive cells (I–K) 
correlates with the percentage staining positive for apoptotic cells (E–G). 
Additionally, in contrast to the proliferation staining whereby CO was 
inhibitory, CO increased positive staining for cell death and activated cas-
pase-3 and simultaneously decreased tissue mass. This offers one expla-
nation as to the mechanism by which restoration of normal pulmonary 
arterial pressure and RV mass occurs. Quantitation of the positively 
stained cells for Ki67 and Apotag/TUNEL are shown (L and M, respec-
tively). (D and H) Negative control stainings for peroxidase and fl  uores-
cent images. The same secondary anti-HRP antibody was used for both 
Ki67 and caspase-3. All images are representative of six to eight sections/
lung from four to six rats/group. Histograms represent means ± SD of 
positively stained cells from 15–20 fi  elds. *, P < 0.01 versus air- or 
  hypoxia-treated rats. Bar, 10 μm.JEM VOL. 203, September 4, 2006  2113 
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Increased mPAP developed in hypoxic animals at 6 wk, as 
indicated by an elevated mPAP of 30 mmHg compared with 
16 mmHg in untreated rats. There was also a corresponding 
30% increase in the RV/LV + IVS ratio (0.35 ± 0.2 in hyp-
oxia-treated rats vs. 0.25 ± 0.25 in control rats; P < 0.01; 
Fig. 2, B and C). In contrast, animals that were treated with 
CO showed a restoration of mPAP, RV/LV + IVS ratios 
similar to those found in untreated wild-type rats (20 ± 4 
mmHg and 0.26 ± 0.4, respectively; Fig. 2, B and C).
CO promotes negative pulmonary vascular remodeling
To reverse vascular hyperplasia and improve PAH, there 
must be a net loss in the cellular mass of the vessel wall and 
the underlying smooth muscle cells. This can occur via de-
creased proliferation and/or increased cell death. An apop-
totic index was determined using Tdt-mediated dUTP-biotin 
nick-end labeling (TUNEL) staining of the pulmonary arte-
rial wall in both the hypoxia and MCT experimental groups 
while proliferation was simultaneously assessed in similar sec-
tions by immunostaining for Ki67. The number of positively 
stained cells was enumerated by a blind experimental proto-
col. In both the hypoxia-treated group (Fig. 3) and in the 
MCT animals (not depicted), we observed elevated Ki67-
positive staining in the smaller arterioles that was markedly 
reduced in the vessels of rats exposed to CO (9 ± 3 vs. 0.5 ± 
0.5 cells/high power fi  eld [HPF], respectively; P < 0.01; Fig. 
3, A–C and J). The opposite eff  ect was observed in assessing 
the degree of cell death in the pulmonary arterial wall. There 
was a marked elevation in the number of apoptotic-positive 
cells in the CO-treated rats versus the number present in the 
MCT- or hypoxia-treated controls (19 ± 3 vs. 2 ± 1 cells/
HPF [MCT] and 14 ± 2 vs. 4 ± 3 [hypoxia]; P < 0.01 for 
both; Fig. 3, D–F and K). Confi  rmatory immunostaining for 
caspase 3 (Fig. 3, I–K) showed a similar pattern as that ob-
served with   TUNEL (Fig. 3, E–G). CO increased the num-
ber of caspase 3–positive cells in the arterial wall of chronic 
Figure 4.  CO increases eNOS expression in PAECs, which is re-
quired for CO to reverse PAH in chronic hypoxia-exposed animals. 
(A–C) Lungs from rats chronically exposed to air (A), hypoxia (B), or hyp-
oxia plus 250 ppm CO for 1 h/d (C) as described in Fig. 6. Lung sections 
were then stained with CD31 (green) to identify PAECs in larger arterioles. 
None of the treatment regimens resulted in a change in CD31 staining or 
morphology, nor were there alterations in PAEC numbers. (E–G) Sections 
from the same lung preparations as above (A–C) stained for eNOS expres-
sion. Only those animals treated with hypoxia in the presence of CO (G) 
showed a substantial increase in eNOS expression, which was not other-
wise modulated in air- and hypoxia-treated animals (E and F, respec-
tively). eNOS-positive staining in the endothelial cell is denoted by arrows. 
There is a trend toward less eNOS positivity in the endothelium of hypoxia-
treated animals, which is consistent with a published report (reference 30). 
Images are representative of six to eight sections/lung from four to 
six rats/group. D and H show secondary antibody negative control 
  images. Bar, 10 μm. (I) Mice exposed to chronic hypoxia develop a time-
dependent increase in mPAP, as expected. Wild-type and nos3−/− mice 
(J and K) were exposed to either chronic hypoxia or chronic hypoxia 
plus CO using the same protocol as described for the rats (see Fig. 6). 
We observed an increase in RV pressure in wild-type mice exposed to 
chronic hypoxia, which was reversed by CO (J). In the nos3−/− mice, 
there was a more modest, but signifi  cant, increase in mean RV pressure. 
CO was unable to reverse this increase in PAH in nos3−/− mice (K). 
  Results represent means ± SD from four to six mice/group. *, P < 0.01 
versus air controls.2114   CARBON MONOXIDE TO TREAT HYPERTENSION | Zuckerbraun et al.
Figure 5.  Interrelationship between CO and NO on endothelial 
cells and PAVSM cells. (A) Kinetics of eNOS and iNOS expression in 
PAECS. Western blot from PAECS exposed to 250 ppm CO shows a time-
dependent increase in eNOS, but not iNOS, expression. β-actin is shown 
as a loading control. Blots are representative of four independent experi-
ments. (B) CO increases NO generation in PAECs. PAECs exposed to CO 
and measured NO production by the changes in DAF fl  uorescence are 
shown. CO increased DAF fl  uorescence as early as 5–15 min. Means ± SD 
of triplicate wells from six to eight independent experiments are given.
 *, P < 0.01 versus time 0. (C) Effects of CO on PAVSM cell proliferation. 
PAVSM cells from rats (shaded bars) or freshly isolated human PAVSM 
cells from an individual with primary pulmonary hypertension (open bars) 
were exposed to CO, and proliferation was assessed by thymidine incor-
poration. Note that CO induced growth arrest in both cell types. Results 
represent means ± SD of triplicate wells from three independent experi-
ments. *, P < 0.001 versus air-treated rats. (D) NO induces cell death in 
PAVSM cells. Rat PAVSM cells were treated with 500 μM of the NO donor 
DETA-NONOate for 36 h, and cell viability was assessed by crystal violet. 
Note that DETA-NONOate–induced cell death was reversed in part by 
treatment with the pancaspase inhibitor ZVAD-fmk. Results represent 
means ± SD of triplicate samples from two independent experiments. 
*, P < 0.001 versus controls; and #, P < 0.05 versus DETA-NONOate–
treated samples. (E) The co-culture schematic is a diagram demonstrating 
the co-culture system that allows cell–cell contact. Cells were seeded and 
treated as described in Materials and methods. (F) PAECs and PAVSM cells 
were co-cultured and exposed to control conditions (5% CO2 ± CO), JEM VOL. 203, September 4, 2006  2115 
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hypoxia- exposed rats with similar quantitative changes as 
seen in the TUNEL-stained tissue (unpublished data).
CO reversal of PAH requires endothelial NO 
synthase (eNOS) expression
We probed whether negative remodeling in CO-treated ani-
mals was occurring as a result of an increased production of 
the vasoregulatory molecule NO. Immunohistochemistry for 
CD31 demonstrated no substantial quantitative diff  erence in 
endothelial cells in hypoxia as compared with the CO-/
hypoxia-treated groups (Fig. 4, A–C). However, staining for 
eNOS (NOS3) showed a marked increase in expression in 
the CO-/hypoxia-treated rats (Fig. 4, E–G). To test whether 
CO required eNOS expression/activation, we exposed wild-
type C57BL/6 and nos3−/− C57BL/6 mice to chronic hyp-
oxia. This is a reliable and well-characterized model of PAH 
that has identical kinetics as in the rat. Fig. 4 I shows the ki-
netic development of PAH in mice exposed to chronic hyp-
oxia. C57BL/6 mice were randomized to groups comprising 
chronic hypoxia treatment with a 1 h/d exposure to 250 ppm 
CO or room air. Mice were exposed to 10% oxygen contin-
uously for 42 d. Mice were treated only during days 22–42 
with inhaled CO (250 ppm for 1h/day) or air. As in the rat, 
signifi  cant improvement in mean right ventricular pressure 
(mRVP) was evidenced in the CO-treated group (P < 0.05; 
Fig. 4 J). To evaluate the contribution of eNOS to the pro-
tective eff  ects of CO, the wild-type and nos3−/− mice were 
exposed to chronic hypoxia for 42 d and either not treated or 
treated with CO on days 22–42. Although CO eff  ectively 
reversed the mRVP in wild-type mice (22 ± 3; P < 0.01), it 
was unable to reverse hypoxia-induced PAH in nos3−/− mice 
(Fig. 4 K). These data implicate eNOS and NO in the pro-
tection aff  orded by CO in restoring normotensive pulmo-
nary arterial pressures.
CO increases eNOS expression in pulmonary artery 
endothelial cells (PAECs)
We found that CO has the same action in vitro as in vivo: 
it stimulates increased protein levels of eNOS in PAECs 
(Fig. 5 A). These cells did not demonstrate increased induc-
ible NOS (iNOS) protein in response to CO and, thus, we 
did not test further the role of iNOS in this model.   Moreover, 
using FACS analyses, PAECS treated with CO demonstrated 
a rapid increase in DAF fl  uorescence, an indicator of NO 
generation (Fig. 5 B). This response is not likely caused by 
increased levels of eNOS protein but could result from func-
tional changes in NOS activity or increased liberation of NO 
from within the cell.
NO increases caspase-dependent cell death of pulmonary 
artery smooth muscle (PAVSM) cells
We next tested whether NO might increase cell death of 
PAVSM cells in vitro. We observed a signifi  cant decrease 
in PAVSM cell proliferation in response to CO in both rat 
PAVSM cells and fresh human PAVSM cells isolated from a 
patient with pulmonary hypertension (P < 0.001; Fig. 5 C). 
We next exposed primary rat PAVSM cells to increasing doses 
(10–500 μM) of the NO donor, DETA-NONOate, and 
measured the number of viable cells by crystal violet staining. 
To diff  erentiate decreased proliferation from increased apop-
tosis, we examined the eff  ects of DETA-NONOate (500μM) 
on PAVSM cells in the presence of the pancaspase inhibitor 
zVAD-fmk (50 μM). NO signifi  cantly decreased cell viabil-
ity and crystal violet staining. This eff  ect was abrogated by 
the addition of zVAD, suggesting that, at least in part, NO 
functions by inducing apoptosis in PAVSM cells (P < 0.05; 
Fig. 5 D).
CO-induced PAVSM cell death is dependent on the presence 
of PAEC and NO generation
Using a co-culture system in which PAVSM cells and PAECs 
were grown on either side of a semipermeable membrane 
with direct physical access to one another (see Fig. 5 E), we 
evaluated whether exposure to hypoxia in the presence of 
CO would modulate the susceptibility of the PAVSM cells to 
cell death without aff  ecting the PAECS and thereby provide 
a mechanism by which CO exerted its eff  ects in vivo in the 
pulmonary vasculature. Using FACS analyses of propidium 
iodide (PI) as a marker of cell viability, we exposed the co-
cultured cells to hypoxia or hypoxia plus 250 ppm CO and 
harvested the cells at 24 and 48 h. At the designated time 
points, each cell type was harvested separately to avoid con-
tamination, prepared as described in Materials and methods, 
and a FACS analysis was performed. Exposure of the co-
  cultures to 1% O2, air, or CO alone had no eff  ect on PAVSM 
cell or PAEC viability, showing no change in PI incorpora-
tion. In contrast, when the cells were exposed to 1% O2 plus 
250 ppm CO for 48 h, there was a marked increase in PI 
staining of the PAVSM cells, increasing greater than fi  vefold 
versus hypoxia alone–treated cells, which was indicative of 
increased cell death. Importantly, there was no observed 
change in viability of the PAECs harvested from any expo-
sure regimen (Fig. 5 F). No changes in PI staining were 
  observed in any treatment group at 24 h.
We conclude that co-culturing and allowing these two 
cell types to interdigitate while being exposed to these 
regimens leads to the ability of these cells to more closely 
  hypoxia, or hypoxia plus CO for 24 and 48 h, and cell viability was deter-
mined by FACS analyses of PI staining, as described in Materials and 
methods. Inclusion of CO in the hypoxia exposure resulted in an increase 
in cell death selectively in PAVSM cells (shaded bars) but not PAECs (open 
bars). Blockade of NOS using L-NAME in the co-culture system reversed 
the effect of CO on cell death. PAECs were unaffected in all treatment 
groups. Results represent means ± SD of six wells/group from two inde-
pendent co-culture experiments. *, P < 0.01 versus control and non-CO–
treated cells; and #, P < 0.03 versus hypoxia-/CO-treated cells. (G) CO is 
unable to increase PAVSM cell death. PAVSM cells (shaded bars) and 
PAECs (open bars) grown in standard non–co-culture systems and ex-
posed to CO showed no differences in cell death. Means ± SD are shown.2116   CARBON MONOXIDE TO TREAT HYPERTENSION | Zuckerbraun et al.
  communicate and thereby mimic the proximity of these cells 
to one another in the in vivo setting. One such mediator for 
which this would be important is NO, which, being highly 
reactive, would most likely not exist in suffi   cient quantities to 
allow communication in a standard co-culture system where 
there is typically a media gap between cell types. To test the 
role of NO in the observed eff  ect with CO in this co-culture 
system, we exposed cells to identical treatments in the pres-
ence and absence of the NOS inhibitor L-NAME. Co-cul-
tures were treated with 250–500 μM L-NAME 1 h before 
exposure. Blockade of NOS in the co-culture system led to a 
reversal of hypoxia plus CO-induced PAVSM cell death as-
sessed by PI staining, with no eff  ects on the PAECS (Fig. 5 F). 
L-NAME alone had no eff  ect on viability in nonhypoxia plus 
CO-treated cells (not depicted).
To address the relevance and importance of co-culture 
experiments, we exposed monolayers of each cell type in 
standard cell culture dishes to identical treatment regimens of 
hypoxia and CO and observed no change in cell death among 
groups (Fig. 5 G).
DISCUSSION
These results demonstrate that daily exposure to a low concen-
tration of CO for 1 h can reverse established PAH in rodents, 
suggesting the potential for a novel and practical therapeutic 
option in the treatment of this devastating disease, keeping 
in mind the necessary caution when extrapolating from an-
imal models to the clinical setting. Nevertheless, these three 
models provide strong evidence to approach clinical testing. 
hmox-1, the gene responsible for endogenous CO generation, 
is highly induced in patients and rodents with PAH, which 
is indicative of its importance as a stress response protein (16, 
19–24). Induction of HO-1 before the disease process starts 
can ameliorate development of PAH and RVH (11). Induc-
ing HO-1 therapeutically (i.e., after the PAH disease process 
has started) has not been tested. Heme oxygenase activity re-
sults in the generation of three products: the bile pigments, 
iron, and CO. The bile pigments, as well as the sequestration 
of iron into ferritin, have been shown to impart potent anti-
oxidant eff  ects. We hypothesized that CO could substitute for 
the eff  ects of HO-1 and might serve to alleviate PAH even as 
a treatment after the disease process has started. It is possible, 
but outside the scope of this study, that biliverdin and ferritin 
administration might impart additional or additive eff  ects oth-
erwise observed with HO-1 induction and, moreover, exert 
protective eff  ects via separate and distinct mechanisms.
In three separate rodent models, we demonstrate that CO 
can reverse established PAH, reduce right heart mass, and 
improve overall health of the animal, as indicated by im-
proved body weight. We did not measure the eff  ects of CO 
on metabolic rate or food intake, which might be altered, as 
well as altered regulation of leptin expression. In the mouse 
chronic hypoxia model, these eff  ects require the expression 
of eNOS and the generation of NO. Whether a similar re-
quirement exists for the other models of PAH is not yet 
known. Decreased eNOS expression has been demonstrated 
in endothelial cells from PAH patients (6). Previous experi-
ments have shown that mice with targeted disruption of the 
eNOS gene exhibit increased mPAP and impaired vasorelax-
ation in response to acetylcholine (25). In our experiments, 
the nos3−/− mice did not demonstrate as great an increase in 
mRVP in response to hypoxia as previously published (25) 
when compared with wild-type mice (29 ± 5 mmHg in 
C57BL/6 hypoxic mice vs. 25 ± 1 mmHg in nos3−/− 
  hypoxic mice, as compared with normoxic values of 18 ± 
2 mmHg and 19 ± 1 mmHg, respectively). Although our 
data are qualitatively consistent with previous experiments, 
there is a quantitative diff   erence that may be explained 
based on the following. The mice we studied were on a 
homozygous C57BL/6 background, whereas mice used in 
previous experiments were on a hybrid background (SV129/
C57BL/6) (25). There is also evidence that CO can modu-
late eNOS activity and expression (26).
Our data suggest that CO and NO work together to exert 
protective therapeutic eff  ects to restore homeostasis. What is 
unclear is which of these two gases directly exerts the thera-
peutic eff  ect, if indeed one of them does (perhaps the combi-
nation is required to achieve the benefi  cial eff  ect). Our data in 
this study suggest that the eff  ect of CO administration is de-
pendent on eNOS and NO production for its salutary eff  ects. 
In a recent study of the eff  ects of CO in a model of hepatitis 
induced by TNF-α and d-galactosamine, we found a more 
complicated series of responses. In order for CO to act, it was 
necessary to have up-regulation of iNOS, production of NO, 
and, subsequently, induction of HO-1. Without each of these 
steps, CO (or NO given directly) had no eff  ect (27).
NO is one of the most potent inducers of HO-1. It is thus 
unclear in the present model of PAH whether the eff  ects of 
NO produced as a consequence of eNOS induction stimu-
lated by CO are mediated directly or via HO-1. Likewise, in 
a model of carotid artery injury in which NO has been shown 
to be protective against intimal proliferation, protection con-
ferred by NO is dependent on HO-1 (unpublished data). 
The enzymatic sources of NO are diff  erent in the liver model 
and in the present PAH model (i.e., iNOS and eNOS, re-
spectively). In both cases, however, what is needed to medi-
ate the eff  ects of CO is NO, and in each case the organ and 
cell responds to provide that second gas. Perhaps these diff  er-
ences refl  ect the mode of injury and/or cell or tissue specifi  c-
ity. The fact that CO diff  erentially regulates the generation of 
NO in diff  erent tissues, but in each to the benefi  t of the cells 
in that tissue, suggests that CO is a component of the natural 
protective system in those organs. Future studies continue to 
focus on understanding this complex relationship between 
CO and NO in terms of cellular and tissue cytoprotection.
The relative roles of CO and NO in PAH are interesting 
and, once again, quite interrelated. The progressive vascular 
hyperplasia that occurs in PAH involves both increased 
PAVSM cell proliferation and decreased regulation of cellular 
apoptosis (28). To reverse established PAH, the arterial wall 
must undergo some degree of negative remodeling to dimin-
ish pulmonary arterial hyperplasia and associated RVH. Our JEM VOL. 203, September 4, 2006  2117 
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co-culture results point to the necessity of cell–cell proxim-
ity, as CO exerted diff  erent eff  ects in this system versus that 
observed in single cell preparations (Fig. 5). The ability of 
CO to induce cell death of the PAVSM cells only in the pres-
ence of PAECs, which are in part NO dependent, makes 
clear the complex interrelationship between these cell types 
and gas molecules. In addition, the important diff  erences that 
arise in cell culture methodologies is critical when comparing 
with the in vivo setting.
Regression of hyperplasia occurs when the balance shifts 
toward decreased proliferation and increased apoptosis in the 
vessel wall. The role of NO in decreasing smooth muscle cell 
proliferation and migration, as well as inhibiting platelet ag-
gregation, is well described (28–30). Similarly, CO suppresses 
platelet aggregation and smooth muscle cell proliferation, 
although the eff  ects of migration are not known. There is 
certainly a distinct possibility that CO acts in part to suppress 
thrombogenesis and explains in part the therapeutic effi   cacy 
of CO in remodeling the pulmonary vasculature. CO expo-
sure has no acute eff  ect in reducing mPAP in normal rodents 
and sheep, which is not surprising because it is a relatively 
weak vasodilator, especially compared with NO. Although 
CO is not benefi  cial as an acute vasodilator, it acts importantly 
to reverse pulmonary artery and RV hypertrophy, acting as 
a therapeutic. NO inhalation is ineff  ective in treating adult 
pulmonary hypertension but acts rapidly and remarkably to 
alleviate neonatal hypertension (29). Perhaps the diff  erences 
of responsiveness and age refl  ect etiological or disease pro-
gression diff  erences.
NO thus clearly plays a role in the eff  ects observed with 
CO. Although the concentrations of the NO donor required 
in vitro to induce cell death of PAVSM cells were high com-
pared with that generated endogenously via the NOSes, we 
argue that perhaps the amount of NO produced by NOS in 
the microenvironment surrounding the juxtaposed endothe-
lial and PAVSM cells allows for very high NO generation 
and exposure. Furthermore, the endogenous NO generated 
might be augmented in the presence of CO such that high 
intracellular concentrations could be achieved. We speculate 
that the eff  ects of CO are pleiotropic in nature, acting di-
rectly on PAVSM cells to decrease proliferation and diminish 
infl  ammation, as well as acting on PAECs to decrease cellular 
injury. That CO also increases levels of endothelial NO, 
which diminishes pulmonary vascular hyperplasia by decreas-
ing PAVSM cell mass via inhibition of proliferation and in-
duction of apoptosis, may be an additional factor over and 
above those just discussed. Our data in the co-culture system 
speak to the necessity of the cell types being juxtaposed and 
interdigitated to some degree to allow adequate exposure to 
the gases and, most likely, other contributing factors such as 
immunomodulatory cytokines and mediators.
The primary goal of these experiments was to determine 
whether CO could treat PAH in a manner that is clinically 
relevant; we believe our results support such a notion. These 
data are the fi  rst to show that CO can act therapeutically in a 
clinically relevant disease model. Moreover, using the regi-
men of 1 h/d represents a reasonable clinical option. It should 
be noted that lower concentrations and shorter exposure 
times have not been tested.
How much CO is delivered to the pulmonary artery and 
right heart tissue by inhalation is unknown and diffi   cult to 
measure reliably with present technology. CO bound to he-
moglobin has an off   rate that presumably helps to determine 
the amount of CO that would reach the pulmonary artery 
and right heart and target eNOS in the PAECs. The high 
diff  usion and nonreactivity of CO must also be factored into 
CO delivery and exposure.
In summary, using three diff  erent models of pulmonary 
hypertension and right heart hypertrophy, we show the fol-
lowing. First, that a low (250 ppm) and short (1 h) daily 
CO exposure regimen can reverse established hypertension, 
resulting in near normal pressures and heart weights. Second, 
that this occurs in part via suppressing growth and increasing 
apoptosis of the vascular smooth muscle cells of the pulmonary 
artery. Third, that the ability of CO to exert its remodeling 
eff  ects requires the expression and function of eNOS/NOS3 
(31). Finally, that NO acts in part as the eff  ector molecule 
to induce cell death of PAVSM cells while preserving the 
endothelial cells. We speculate that the NO that is gener-
ated acts in part to correct endothelial cell dysfunction that 
then leads to apoptosis of the dysregulated, hyperproliferative 
smooth muscle cells. Collectively, we demonstrate that CO 
and NO act in concert to exert benefi  cial eff  ects in the car-
diopulmonary system and reverse established pathology, and 
show for the fi  rst time that CO can act therapeutically. Is it 
possible that a combination gas therapy can be used? Expo-
sure to inhaled NO to act as an acute pulmonary vasodilator 
initially, followed by intermittent exposure to CO, such as 
demonstrated in this paper, to reverse the pathology could 
perhaps be a potential therapeutic regimen. Currently there 
are limited alternatives for treatment of PAH (1). A recent 
report showed some success in treatment of PAH with a gene 
therapy approach to block prosurvival factors such as sur-
vivin, but using this clinically may prove diffi   cult (32). The 
regimen of CO exposure we present is clinically feasible and 
could prove to be a useful therapy in the treatment of PAH.
MATERIALS AND METHODS
Animal models. The therapeutic exposure regimens for the MCT and 
chronic hypoxia models are depicted in Fig. 6. All animal protocols were 
approved by the animal care and use committee at the University of Pitts-
burgh School of Medicine and Beth Israel Deaconess Medical Center. Ani-
mals were allowed to acclimate 1 wk before experimentation with food and 
water ad libitum.
MCT. MCT (Sigma-Aldrich), dissolved in 1 N HCl neutralized with 0.5 N 
NaOH and diluted with PBS, was given as a single 50-mg/kg s.c. injection to 
male Sprague-Dawley rats weighing between 250 and 260g (Harlan), whereas 
control rats were injected with the same volume of saline. 250 ppm CO was 
administered for 2 wk at 1 h/d for the indicated time interval (Fig. 6).
Chronic hypoxia. Male Sprague Dawley rats were purchased from Harlan 
and allowed to acclimate for 1 wk with access to food and water ad libitum. 
Animals were placed in an airtight plexiglass chamber and exposed to 10% 2118   CARBON MONOXIDE TO TREAT HYPERTENSION | Zuckerbraun et al.
O2 continuously for 6 wk. 3 wk into the exposure, rats were removed and 
placed in another airtight chamber and exposed to 250 ppm CO (in the air) 
or air (controls) for 1 h and then immediately returned to the 10% O2 
  chamber (see Fig. 6). In vivo CO exposures were performed as previously 
described (7). This was repeated daily for the remaining 3 wk. PAH was 
  determined on day 42. For the mouse hypoxia experiments, male C57BL6/J 
and enos−/−/nos3−/− mice were purchased from The Jackson Laboratory and 
allowed to acclimate for 1 wk. The mice were exposed in an identical man-
ner as that of the rat. mRVP was measured on day 42.
Male FHH rats (Charles River Laboratories) at 10 wk of age weighing 
 250–300g were purchased and allowed to acclimate 2 wk before experi-
mentation. FHH rats at this age are known to exhibit PAH. We then started 
CO exposure (250ppm for 1h/d) for a 3-wk duration and determined PAH 
after 3 wk. All animal protocols were approved by the University of Pitts-
burgh School of Medicine Animal Care and Use Committee.
Determination of PAH. At the end of the experiment, the animals were 
anesthetized, and RV pressures were measured using a fl  uid-fi  lled pressure 
transducer connected to a PC-driven PowerLab (ADInstruments). Animal 
body weights were also measured before and after all treatments. Hearts and 
lungs were then harvested, the hearts were dissected, and the mass of the RV 
and LV plus IVS was measured. Sections of the lung and heart were fi  xed 
in 2% paraformaldehyde and snap frozen in liquid N2. 7-μm sections were 
then immunostained.
Pulmonary artery morphometrics. Paraffi   n-embedded  lung  sections 
were stained with hematoxylin and eosin. Images for arterioles were captured 
with a microscope digital camera system (Provus; Olympus), and arterial area 
was measured using an image analysis program (Metamorph 6.2; Univer-
sal Imaging Corp.). Percent wall thickness was calculated by the following 
  formula: wall thickness (%) = area external − area internal/area external × 
100, where area external and area internal are the areas bounded by external 
elastic lamina and the lumen, respectively. 10 vessels/rat of comparable size 
from the lungs of fi  ve diff  erent rats from both MCT control and CO-treated 
(days 29–42) groups were determined, as well as untreated controls.
Cell culture. PAECs and vascular smooth muscle cells were cultured in 
DMEM containing 10% FBS and 100 μg/ml gentamicin. Cells were ex-
posed to 250 ppm CO or air using a bioactive gas controlling system custom 
designed and built by Biospherix Ltd. To achieve a concentration of 250 
ppm, 1% (10,000 ppm) CO (Lifegas Inc.) was mixed with 5% CO2/20.8% 
O2/74% N2 and controlled by software (Anafaze; Watfl  ow) on a computer 
(Dimension DIM2400; Dell).
Co-culture of PAVSM cells and PAECs. PAVSM cells at passages 2–5 
were seeded on the underside of collagen-impregnated, 24-mm permeable 
support inserts (Transwell; Corning) and placed in the cell culture incubator 
for 2 h, after which PAECs at passages 3–6 were seeded on the upper com-
partment and fl  ip side of support. The PAEC/PAVSM cell co-culture inserts 
were then placed in six-well plates with media on both the upper and lower 
compartments. The 400-mm membrane pore size was specifi  cally chosen to 
allow for interdigitation of cell processes between the two compartments, as 
well as the exchange of media and soluble mediators. However, migration of 
either cell type is highly improbable. On the day of the experiment, the 
PAEC/PAVSM cell co-cultures were exposed for either 24 or 48 h to either 
hypoxia (1% O2/5% CO2/balance N2), CO (250 ppm/5% CO2/balance N2), 
hypoxia plus CO, or 5% CO2 in air. A separate group of cells were pre-
treated with 500 μM L-NAME (Sigma-Aldrich) for 1 h before exposures for 
24 and 48 h to hypoxia/CO. L-NAME was added once daily. At the end of 
the experiment, cells were harvested by trypsinization and subjected to 
FACS analysis for cell viability. Cells were observed before harvest. Based on 
morphological characteristics, contamination of each side by the other cell 
type was confi  rmed.
PI staining was performed using standard techniques. In brief, forward 
and side scatter gates were set to include cells but to exclude debris. Excita-
tion was set at 488 nm, and emission was recorded on a sensor for PI (575 ± 
10 nm; FL2; Sigma-Aldrich). Cell cycle and DNA content were detected 
with PI. Each experimental set was performed fi  ve times, and the data were 
analyzed with software (CellQuest; BD Biosciences).
DAF fl  uorescence as a measure of intracellular production of NO. 
PAECs were incubated with air or 250 ppm CO for 5–15 min. Cells were 
loaded with 5 μM 4-amino-5-methylamino-2’,7’-difl  uorofl  uorscein (DAFH-
DA; Invitrogen) 15 min before the harvest time point. DAFH-DA is a se-
lective fl  ourophor for NO. Cells were then washed, resuspended in FACS 
buff  er (PBS + 1% FBS), and intensity of fl  uorescence was read at 503 nm for 
excitation and at 529 nm for emission wavelength, respectively. Macrophages 
treated with PMA were used as a positive control (unpublished data).
Immunoblotting. Cell and tissue lysates were separated by SDS-PAGE 
and blotted as described previously (14). Blots were incubated with primary 
rabbit anti-eNOS or -iNOS (BD Biosciences). Membranes were then 
washed in TTBS and visualized using horseradish peroxidase (HRP)–conju-
gated antibody against rabbit or mouse IgG and the enhanced chemilumi-
nescence reagents (GE Healthcare), as per the manufacturer’s instructions. 
To confi  rm equal loading, blots were reprobed with mouse mAb targeting 
β-actin (Abcam Inc.).
Immunostaining. Expression of Ki67, eNOS, and activated caspase-3 
were detected in 5-μm lung sections with antibodies from Cell Signaling. 
Protein expression was visualized with HRP-conjugated goat anti–mouse or 
goat anti–rabbit antibodies (Invitrogen). Apoptotic cells were detected using 
a kit from Chemicon to detect TUNEL-positive cells, according to the 
manufacturer’s instructions, including negative control staining. Nuclei were 
visualized with DAPI (Sigma-Aldrich). Staining was visualized in a blinded 
fashion on a microscope (Axiovert; Carl Zeiss MicroImagin, Inc.). 8–10 im-
ages were captured at random from each animal. Cell counts, where indi-
cated, were performed blinded and expressed as cells/HPF.
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